TC Biopharm   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Holytown United Kingdom (2013)

Organization Overview

First Clinical Trial
2015
NCT02459067
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

TC Biopharm

Active Ingredients

Drugs in Phase 3 Trials (1)

immunicell (1 trial)

Drugs in Phase 2 Trials (1)

tcb008 (1 trial)

Drugs in Phase 1 Trials (1)

allogeneic gamma-delta t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Renal Cell (Phase 3)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Melanoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3